Related Experiment Video

Updated: Mar 18, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K

Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV

Christine E MacBrayne1, Jennifer J Kiser1

  • 1Department of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|July 2, 2016
PubMed

Insights

Direct-acting antiviral agents (DAAs) can cure over 90% of hepatitis C virus (HCV) infections in people with human immunodeficiency virus (HIV). Careful review of drug interactions between DAAs and HIV medications is crucial for safe and effective treatment.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Pharmacology

Background:

  • High prevalence of hepatitis C virus (HCV) coinfection in human immunodeficiency virus (HIV)-infected individuals due to shared transmission routes.
  • HIV accelerates HCV disease progression, necessitating prompt HCV treatment in coinfected patients.
  • Emergence of highly effective direct-acting antiviral agents (DAAs) for HCV treatment with cure rates exceeding 90%.

Purpose of the Study:

  • To review the clinical pharmacology of DAAs used for HCV treatment.
  • To analyze the drug interaction potential between DAAs and antiretroviral agents used for HIV management.
  • To identify knowledge gaps in managing HCV in HIV coinfected individuals.

Main Methods:

  • Review of regulatory-approved DAAs in the US and Europe.
  • Examination of clinical pharmacology and drug interaction data for DAAs.
  • Analysis of published interaction studies between DAAs and antiretroviral agents.
  • Inclusion of agents in late-stage clinical development.

Main Results:

  • DAAs offer high cure rates (>90%) for HCV in various populations, including those with HIV.
  • Potential for drug interactions between DAAs and antiretroviral agents is a key consideration.
  • Specific interaction profiles and management strategies are being established.

Conclusions:

  • HCV treatment with DAAs is highly effective in HIV coinfected individuals.
  • Understanding and managing drug-drug interactions is paramount for successful HCV treatment outcomes.
  • Further research is needed to address remaining knowledge gaps in pharmacologic management.

Keywords:
coinfectiondirect-acting antiviralsdrug interactionshepatitis C virushuman immunodeficiency virus

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
327
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
6
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
324
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.3K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
278